Gut Microbes: Amoxicillin vs. Tetracycline Quadruple Therapy as a First-line Treatment for Helicobacter Pylori Infection

Recently, a multicenter, randomized controlled, non-inferiority trial compared the efficacy and safety of modified quadruple therapy and bismuth quadruple therapy as a first-line eradication program for Helicobacter pylori infection .
The results of the study have been published in Gut Microbes
.

The study included subjects who were diagnosed with Helicobacter pylori infection through endoscopy and were randomly assigned to receive modified quadruple therapy (rabeprazole 20 mg bid, amoxicillin 1 g bid, metronidazole 500 mg tid, and bismuth nitrite 300 mg qid [ Element bismuth 480mg]; PAMB) or bismuth-containing quadruple therapy (rabeprazole 20mg bid, bismuth nitrite 300mg qid, metronidazole 500mg tid, tetracycline 500mg qid; PBMT) for 14 days
.

As a result, a total of 233 participants were randomly assigned, 27 people were missing, and 4 people violated the agreement
.

In summary, the modified quadruple therapy consisting of rabeprazole, amoxicillin, metronidazole and bismuth is an effective first-line therapy for Helicobacter pylori infection in areas where clarithromycin and metronidazole are highly resistant

Original source:

Chang Seok Bang, et al.